Integrated green algal technology for bioremediation and biofuel.

Sustainable non-food energy biomass and cost-effective ways to produce renewable energy technologies from this biomass are continuously emerging. Algae are capable of producing lipids and hydrocarbons quickly and their photosynthetic abilities make them a promising candidate for an alternative energy source. In addition, their favorable carbon life cycle and a renewed focus on rural economic development are attractive factors. In this review the focus is mainly on the integrated approach of algae culture for bioremediation and oil-based biofuel production with mention of possible other value-added benefits of using algae for those purposes.

Quantitative assessment of macrophage functions in repair and fibrosis.

Macrophages play key roles in wound repair and fibrosis by regulating extracellular matrix turnover. Macrophages can process matrix components themselves, but also recruit and alter the functions of other cell types that directly build or degrade extracellular matrix. Classically activated macrophages (CAM, also called M1) tend to promote tissue injury while alternatively activated macrophages (AAM, also called M2) are often linked with the mechanisms of wound repair and fibrosis. However, rather than promoting collagen deposition, recent studies suggest that arginase-1-expressing AAM suppress chronic inflammation and fibrosis by inhibiting antigen-specific T cell responses. This unit describes methods to measure arginase activity in macrophages and whole tissues as well as assays to quantify the T cell suppressive activity of AAMs. Modified hydroxyproline and soluble collagen assays that can be used to quantify collagen levels in tissues and brochoalveolar lavage fluid are also described. The protocols in this unit should provide the investigator with all the necessary information required to measure arginase activity and to correlate the observed activity with the progression and resolution of fibrosis.

Reviving the vascular surgeon-scientist: an interim assessment of the jointly sponsored Lifeline Foundation/National Heart, Lung, and Blood Institute William J. von Liebig Mentored Clinical Scientist Development (K08) Program.

The Lifeline Foundation/National Heart, Lung, and Blood Institute William J. von Liebig Mentored Clinical Scientist Development (K08) Award program was established as a unique partnership to support vascular surgeon-scientists. Between 1999 and 2005, 39 applications were submitted, and the overall funding rate was 49% (14 von Liebig K08s and 5 additional NHLBI K08s). Vascular surgeon K08 recipients (median age, 38 years) had held faculty appointments for 2.5 +/- 0.4 years, with 2.6 +/- 0.2 years of previous research experience and 28.4 +/- 6.2 publications. These individuals subsequently authored 5.1 +/- 0.8 peer-reviewed publications per recipient per year, of which 35% were research and 65% were clinical. Six of seven holding the K08 over 3 years had received academic promotion, and all five completing the 5-year award had achieved independent investigator status with National Institutes of Health support. The von Liebig K08 program has therefore been an effective vehicle to stimulate research career development in the field of vascular surgery.

Monte Carlo Simulations of Water Adsorption Isotherms in Silicalite and Dealuminated Zeolite Y.

The affinity that adsorbents have for water can influence their effectiveness in organics removal from drinking water due to competitive adsorption. The extent of the affinity of microporous zeolites for water is determined, in part, by AlO4(-) tetrahedral sites (T-sites) in the crystal lattice and lattice defects in the form of silanol nests. In this study, water adsorption isotherms in silicalite and in dealuminated zeolite Y (DAY) were simulated using the Compass force-field. The results show that the simulations can predict the shape of water adsorption isotherms and predict adsorption levels comparable to literature results. Moreover, simulations revealed that the results are influenced significantly by the presence of AlO4(-) T-sites. The results confirm the capacity of the Compass force-field to predict water sorption properties in silicalite and in DAY.

Type II endoleak after endovascular abdominal aortic aneurysm repair: a conservative approach with selective intervention is safe and cost-effective.

OBJECTIVES: The conservative versus therapeutic approach to type II endoleak after endovascular repair of abdominal aortic aneurysm (EVAR) has been controversial. The purpose of this study was to evaluate the safety and cost-effectiveness of the conservative approach of embolizing type II endoleak only when persistent for more than 6 months and associated with aneurysm sac growth of 5 mm or more. METHODS: Data for 486 consecutive patients who underwent EVAR were analyzed for incidence and outcome of type II endoleaks. Spiral computed tomography (CT) scans were reviewed, and patient outcome was evaluated at either office visit or telephone contact. Patients with new or late-appearing type II endoleak were evaluated with spiral CT at 6-month intervals to evaluate both persistence of the endoleak and size of the aneurysm sac. Persistent (>or=6 months) type II endoleak and aneurysm sac growth of 5 mm or greater were treated with either translumbar glue or coil embolization of the lumbar source, or transarterial coil embolization of the inferior mesenteric artery. RESULTS: Type II endoleaks were detected in 90 (18.5%) patients. With a mean follow-up of 21.7 +/- 16 months, only 35 (7.2%) patients had type II endoleak that persisted for 6 months or longer. Aneurysm sac enlargement was noted in 5 patients, representing 1% of the total series. All 5 patients underwent successful translumbar sac embolization (n = 4) or transarterial inferior mesenteric artery embolization (n = 4) at a mean follow-up of 18.2 +/- 8.0 months, with no recurrence or aneurysm sac growth. No patient with treated or untreated type II endoleak has had rupture of the aneurysm. The mean global cost for treatment of persistent type II endoleak associated with aneurysm sac growth was US dollars 6695.50 (hospital cost plus physician reimbursement). Treatment in the 30 patients with persistent type II endoleak but no aneurysm sac growth would have represented an additional cost of US dollars 200000 or more. The presence or absence of a type II endoleak did not affect survival (78% vs 73%) at 48 months. CONCLUSIONS: Selective intervention to treat type II endoleak that persists for 6 months and is associated with aneurysm enlargement seems to be both safe and cost-effective. Longer follow-up will determine whether this conservative approach to management of type II endoleak is the standard of care.